Gülnur Karadaş, A. Erdoğan, F. Ekinci, M. Çivi, Gamze Göksel
ABS TRACT Objective: In this study, we investigated the effects of nutritional support on the quality of life of cancer patients, determined nutritional deficiencies, eliminated it at the earliest, and established a built-in system to prolong patient survival. Material and Methods: We included 459 patients admitted to the medical oncology outpatient clinic, diagnosed with cancer and receiving chemotherapy; 59 of 459 pa- tients were diagnosed with malnutrition in the study using the Nutritional Risk Screening (NRS) 2002 nutritional status scale. Appropriate en-teral nutrition support was provided to the patients, and control evaluations were made four times at intervals of 28 days. In these controls, information on the height, weight, and the right and left middle arm circumference of the patients was recorded. Along with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-30 (EORTC QLQ-30) Quality of Life Scale, the Hospital Anx- iety and Depression Scale was also used. Results: A statistically significant difference was found in the NRS 2002 scores of the patients regarding the adequacy of intake, protein and calorie requirement, functional status, and the symptom scale. The anxiety and depression scores of the patients decreased in all the controls, and the most noticeable decrease occurred at the end of the third control. Conclusion: Evaluating malnutrition and providing adequate nutritional support to cancer patients improves body composition and the quality of life by reducing anxiety and depression.
{"title":"Effects of Nutritional Support on the Quality of Life of Cancer Patients","authors":"Gülnur Karadaş, A. Erdoğan, F. Ekinci, M. Çivi, Gamze Göksel","doi":"10.37047/jos.2022-89699","DOIUrl":"https://doi.org/10.37047/jos.2022-89699","url":null,"abstract":"ABS TRACT Objective: In this study, we investigated the effects of nutritional support on the quality of life of cancer patients, determined nutritional deficiencies, eliminated it at the earliest, and established a built-in system to prolong patient survival. Material and Methods: We included 459 patients admitted to the medical oncology outpatient clinic, diagnosed with cancer and receiving chemotherapy; 59 of 459 pa- tients were diagnosed with malnutrition in the study using the Nutritional Risk Screening (NRS) 2002 nutritional status scale. Appropriate en-teral nutrition support was provided to the patients, and control evaluations were made four times at intervals of 28 days. In these controls, information on the height, weight, and the right and left middle arm circumference of the patients was recorded. Along with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-30 (EORTC QLQ-30) Quality of Life Scale, the Hospital Anx- iety and Depression Scale was also used. Results: A statistically significant difference was found in the NRS 2002 scores of the patients regarding the adequacy of intake, protein and calorie requirement, functional status, and the symptom scale. The anxiety and depression scores of the patients decreased in all the controls, and the most noticeable decrease occurred at the end of the third control. Conclusion: Evaluating malnutrition and providing adequate nutritional support to cancer patients improves body composition and the quality of life by reducing anxiety and depression.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69822173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ö. Dülgar, Sevgi Ferik, S. Ay, E. Bayram, T. Şakalar
ABS TRACT Objective: Sleep quality (SQ) may decrease in breast cancer patients following the treatment. The aim of this study was to as- sess the SQ of breast cancer patients treated with Cyclin-dependent kinase(CDK) 4–6 inhibitor plus endocrine therapy(ET). Metarial and Methods: The data were collected from three different cancer centers. Eighty consecutive patients were included in this study. The Pittsburg Sleep Quality Index(PSQI) was employed for the assessment of the SQ in metastatic breast cancer patients after receiving treatment with CDK4–6 inhibitors plus ET for at least three months. Results: The PSQI scores revealed that 68.8% of patients treated with CDK4–6 plus ET have poor SQ. The mean score of the PSQI was 8 (ranging from 1-17). Univariate analysis was employed, revealing a significantly higher sleep latency (p= 0.024), sleep disturbance (p= 0.011), and daytime dysfunction (p= 0.012) in patients receiving letrozole as compared to pa- tients treated with Fulvestrant. Similarly, the mean score of the PSQI was also higher in letrozole-treated patients in comparison with Fulvestrant-treated patients (p= 0.042). The multivariate analysis revealed a significantly higher rate of daytime dysfunction in letrozole-treated patients as compared to Fulvestrant-treated patients (The odds ratio was 0.51, 95% confidence interval, 0.30 to 0.86; p=0.008). In addition, no significant difference was observed in the sleep quality of patients receiving either Ribociclib or Palbociclib. Conclusion: The study evi- dently shows worsening of SQ in patients receiving letrozole in comparison with patients receiving Fulvestrant. CDK4–6 inhibitors have a similar effect on SQ.
{"title":"Sleep Quality Analysis in Metastatic Breast Cancer Patients Receiving Cyclin-Dependent Kinase 4-6 Inhibitor","authors":"Ö. Dülgar, Sevgi Ferik, S. Ay, E. Bayram, T. Şakalar","doi":"10.37047/jos.2022-91240","DOIUrl":"https://doi.org/10.37047/jos.2022-91240","url":null,"abstract":"ABS TRACT Objective: Sleep quality (SQ) may decrease in breast cancer patients following the treatment. The aim of this study was to as- sess the SQ of breast cancer patients treated with Cyclin-dependent kinase(CDK) 4–6 inhibitor plus endocrine therapy(ET). Metarial and Methods: The data were collected from three different cancer centers. Eighty consecutive patients were included in this study. The Pittsburg Sleep Quality Index(PSQI) was employed for the assessment of the SQ in metastatic breast cancer patients after receiving treatment with CDK4–6 inhibitors plus ET for at least three months. Results: The PSQI scores revealed that 68.8% of patients treated with CDK4–6 plus ET have poor SQ. The mean score of the PSQI was 8 (ranging from 1-17). Univariate analysis was employed, revealing a significantly higher sleep latency (p= 0.024), sleep disturbance (p= 0.011), and daytime dysfunction (p= 0.012) in patients receiving letrozole as compared to pa- tients treated with Fulvestrant. Similarly, the mean score of the PSQI was also higher in letrozole-treated patients in comparison with Fulvestrant-treated patients (p= 0.042). The multivariate analysis revealed a significantly higher rate of daytime dysfunction in letrozole-treated patients as compared to Fulvestrant-treated patients (The odds ratio was 0.51, 95% confidence interval, 0.30 to 0.86; p=0.008). In addition, no significant difference was observed in the sleep quality of patients receiving either Ribociclib or Palbociclib. Conclusion: The study evi- dently shows worsening of SQ in patients receiving letrozole in comparison with patients receiving Fulvestrant. CDK4–6 inhibitors have a similar effect on SQ.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69823542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Aktürk Esen, Esra Fırat Oğuz, Y. Ergün, Denizcan Hastürk, M. Bardakçi, G. Ucar, M. Şendur, I. Ateş, Ö. Erel, D. Uncu
ABS TRACT Objective: This study aimed to assess two oxidative stress (OxS) markers, thiol-disulfide (TD) homeostasis and ischemia-mod- ified albumin (IMA), in newly diagnosed metastatic pancreatic cancer (PC) patients. Material and Methods: This was a prospective case-control study including two groups: 30 cases each of histopathologically confirmed metastatic PC patients and healthy controls. Serum TD and IMA levels were measured and compared in both groups. Moreover, the association between TD and IMA levels, as well as overall survival (OS) in the patient group, were investigated. Results: Both native thiol (NT) and total thiol (TT) levels significantly decreased in the patient group than in the control group (p=0.016 and p=0.009, respectively). However, disulfide (D) and IMA levels were similar between the two groups (p=0.056 and p=0.068, respectively). Both the D/NT and D/TT ratios were significantly higher in the patient group (p=0.005 and p=0.004, respectively) than in the control group. Additionally, no association was observed between IMA, TD homeostasis, and OS. Conclusion: Our results showed that increased OxS levels affected PC progression. With the development of newer targeted therapeutics for OxS, the progression of PC in individuals with higher genetic risk may be prevented.
{"title":"Ischemia-Modified Albumin and Thiol-Disulfide Homeostasis in Metastatic Pancreatic Cancer","authors":"S. Aktürk Esen, Esra Fırat Oğuz, Y. Ergün, Denizcan Hastürk, M. Bardakçi, G. Ucar, M. Şendur, I. Ateş, Ö. Erel, D. Uncu","doi":"10.37047/jos.2022-93441","DOIUrl":"https://doi.org/10.37047/jos.2022-93441","url":null,"abstract":"ABS TRACT Objective: This study aimed to assess two oxidative stress (OxS) markers, thiol-disulfide (TD) homeostasis and ischemia-mod- ified albumin (IMA), in newly diagnosed metastatic pancreatic cancer (PC) patients. Material and Methods: This was a prospective case-control study including two groups: 30 cases each of histopathologically confirmed metastatic PC patients and healthy controls. Serum TD and IMA levels were measured and compared in both groups. Moreover, the association between TD and IMA levels, as well as overall survival (OS) in the patient group, were investigated. Results: Both native thiol (NT) and total thiol (TT) levels significantly decreased in the patient group than in the control group (p=0.016 and p=0.009, respectively). However, disulfide (D) and IMA levels were similar between the two groups (p=0.056 and p=0.068, respectively). Both the D/NT and D/TT ratios were significantly higher in the patient group (p=0.005 and p=0.004, respectively) than in the control group. Additionally, no association was observed between IMA, TD homeostasis, and OS. Conclusion: Our results showed that increased OxS levels affected PC progression. With the development of newer targeted therapeutics for OxS, the progression of PC in individuals with higher genetic risk may be prevented.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69823786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ABS TRACT Objective: This study aimed to investigate the clinical outcomes of site-specific therapy (SST) in patients with metastatic ade- nocarcinoma of unknown primary (MACUP). Material and Methods: A retrospective observational study was conducted, including patients diagnosed with MACUP. Clinicopathological features and clinical outcomes of SST were evaluated. Results: Sixty patients were included in the study. The median age was 61.5 (minimum-maximum: 31.1-76.1) years, and 40.0% of the patients (n=24) were 65 years or older. The progression-free survival (mPFS) was 4.7 months [95% confidence interval (CI): 3.7-5.7] with the first-line treatment in the whole group. The mPFS was 4.1 months (95% CI: 2.9-5.2), 4.7 months (95% CI: 3.0-6.3), and 9.3 months (95% CI: 6.1-12.6) in the gemcitabine plus cisplatin, carboplatin plus paclitaxel, and mFOLFOX-6 groups, respectively. The overall survival (mOS) was 14.1 months (95% CI: 9.2-18.8) in the whole group. The mOS was 9.2 months (95% CI: 3.3-14.3), 8.5 months (95% CI: 3.8-13.2), and 15.5 months (95% CI: 9.3-18.8) in the gemcitabine plus cisplatin, carboplatin plus paclitaxel, and mFOLFOX-6 groups, respectively. Conclusion: Patients with colorectal-derived can- cers of our cohort, considered as a “more sensitive” type, seemed to benefit more from immunohistochemistry-based (IHC-based) SST. However, SST determination using genomic profiling is a gold standard, and IHC also offered valuable information.
{"title":"Clinicopathological Features and Clinical Outcomes of Metastatic Adenocarcinoma of Unknown Primary: A Single Center Experience","authors":"F. Gürler, Aysegul Ilhan Güleşen, B. Öksüzoğlu","doi":"10.37047/jos.2022-91381","DOIUrl":"https://doi.org/10.37047/jos.2022-91381","url":null,"abstract":"ABS TRACT Objective: This study aimed to investigate the clinical outcomes of site-specific therapy (SST) in patients with metastatic ade- nocarcinoma of unknown primary (MACUP). Material and Methods: A retrospective observational study was conducted, including patients diagnosed with MACUP. Clinicopathological features and clinical outcomes of SST were evaluated. Results: Sixty patients were included in the study. The median age was 61.5 (minimum-maximum: 31.1-76.1) years, and 40.0% of the patients (n=24) were 65 years or older. The progression-free survival (mPFS) was 4.7 months [95% confidence interval (CI): 3.7-5.7] with the first-line treatment in the whole group. The mPFS was 4.1 months (95% CI: 2.9-5.2), 4.7 months (95% CI: 3.0-6.3), and 9.3 months (95% CI: 6.1-12.6) in the gemcitabine plus cisplatin, carboplatin plus paclitaxel, and mFOLFOX-6 groups, respectively. The overall survival (mOS) was 14.1 months (95% CI: 9.2-18.8) in the whole group. The mOS was 9.2 months (95% CI: 3.3-14.3), 8.5 months (95% CI: 3.8-13.2), and 15.5 months (95% CI: 9.3-18.8) in the gemcitabine plus cisplatin, carboplatin plus paclitaxel, and mFOLFOX-6 groups, respectively. Conclusion: Patients with colorectal-derived can- cers of our cohort, considered as a “more sensitive” type, seemed to benefit more from immunohistochemistry-based (IHC-based) SST. However, SST determination using genomic profiling is a gold standard, and IHC also offered valuable information.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69823988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Mono-Immunotherapy in Non-Small Cell Lung Cancer: Controversies and Challenges","authors":"T. Kus","doi":"10.37047/jos.2022-93252","DOIUrl":"https://doi.org/10.37047/jos.2022-93252","url":null,"abstract":"the","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69824047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ABS TRACT Objective: The purpose of this study is to evaluate the association between albumin-bilirubin (ALBI) grade and right and left colon in colon cancer (CC) patients with liver metastases who received regorafenib treatment. Material and Methods: This retrospective study included 126 patients treated with regorafenib and was divided into normal-ALBI (ALBI Grade 1) and high-ALBI groups (ALBI Grades 2 and 3). The optimal cut-off values of neutrophil-lymphocyte ratio and prognostic nutritional index (PNI), evaluated by receiver operating characteristic curve analysis, were 4.41 and 40.85, respectively. The associations between parameters with survival were analyzed using Ka- plan-Meier curves and compared by the log-rank test. Cox proportional hazards regression analyzes were used to evaluate the prognostic significance of the parameters for progression-free survival (PFS) and overall survival (OS). Results: The ALBI group for OS (p=0.043) in the right CC (RCC) and the number of metastatic organs for PFS (p=0.048) were found to be independent prognostic variables. The overall response rate (ORR) was significantly higher in the group with low ALBI for RCC. In RCC, adverse events (AE) were higher in the group with high ALBI than in the normal group (p=0.028). The number of metastatic organs in left CC (LCC) (p=0.008, p<0.001, p=0.042) was found to be independent prognostic for both PFS and OS. Both ORR and disease control rate were significantly higher in the LCC group with high PNI. Conclusion: In RCC cases with liver metastases treated with regorafenib, the ALBI group was significantly associated with prognosis, survival, response rates, and AE. ALBI grade should be considered in RCC patients receiving regorafenib therapy.
{"title":"The Relationship of Albumin-Bilirubin Grade with Right and Left Colon in Patients with Colon Cancer Treated with Regorafenib","authors":"H. Yılmaz, E. Oktay","doi":"10.37047/jos.2022-89000","DOIUrl":"https://doi.org/10.37047/jos.2022-89000","url":null,"abstract":"ABS TRACT Objective: The purpose of this study is to evaluate the association between albumin-bilirubin (ALBI) grade and right and left colon in colon cancer (CC) patients with liver metastases who received regorafenib treatment. Material and Methods: This retrospective study included 126 patients treated with regorafenib and was divided into normal-ALBI (ALBI Grade 1) and high-ALBI groups (ALBI Grades 2 and 3). The optimal cut-off values of neutrophil-lymphocyte ratio and prognostic nutritional index (PNI), evaluated by receiver operating characteristic curve analysis, were 4.41 and 40.85, respectively. The associations between parameters with survival were analyzed using Ka- plan-Meier curves and compared by the log-rank test. Cox proportional hazards regression analyzes were used to evaluate the prognostic significance of the parameters for progression-free survival (PFS) and overall survival (OS). Results: The ALBI group for OS (p=0.043) in the right CC (RCC) and the number of metastatic organs for PFS (p=0.048) were found to be independent prognostic variables. The overall response rate (ORR) was significantly higher in the group with low ALBI for RCC. In RCC, adverse events (AE) were higher in the group with high ALBI than in the normal group (p=0.028). The number of metastatic organs in left CC (LCC) (p=0.008, p<0.001, p=0.042) was found to be independent prognostic for both PFS and OS. Both ORR and disease control rate were significantly higher in the LCC group with high PNI. Conclusion: In RCC cases with liver metastases treated with regorafenib, the ALBI group was significantly associated with prognosis, survival, response rates, and AE. ALBI grade should be considered in RCC patients receiving regorafenib therapy.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69822318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ABS TRACT Cell fusion is a cellular mechanism in which cell membranes of two or more cells fuse to become a new hybrid cell. Cell fusion plays an important role in several physiological tasks such as fertilization, organogenesis, inflammatory response, and tissue repair. However, cell fusion aids in the development of a wide range of pathological conditions such as inflammation and cancer. Cell fusion of normal somatic cells is a tightly controlled process that is limited to only a few cell types in humans, resulting in terminally differentiated multinucleated cells incapable of proliferation. However, this tightly controlled process becomes dysregulated due to genetic alterations and leads to the develop- ment of cancer. In this review, the implications of cell fusion and its role in carcinogenesis are discussed in detail.
{"title":"Tumor Microenvironment and Mechanisms of Cancer Metastasis: An Overlooked Fact: Cell Fusion","authors":"M. Yıldırım, Ö. Sever","doi":"10.37047/jos.2022-89872","DOIUrl":"https://doi.org/10.37047/jos.2022-89872","url":null,"abstract":"ABS TRACT Cell fusion is a cellular mechanism in which cell membranes of two or more cells fuse to become a new hybrid cell. Cell fusion plays an important role in several physiological tasks such as fertilization, organogenesis, inflammatory response, and tissue repair. However, cell fusion aids in the development of a wide range of pathological conditions such as inflammation and cancer. Cell fusion of normal somatic cells is a tightly controlled process that is limited to only a few cell types in humans, resulting in terminally differentiated multinucleated cells incapable of proliferation. However, this tightly controlled process becomes dysregulated due to genetic alterations and leads to the develop- ment of cancer. In this review, the implications of cell fusion and its role in carcinogenesis are discussed in detail.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69823067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Atçı, O. Can, Şaban Seçmeler, A. Sakin, S. Ay, Ş. Cihan, O. Selvi, Ç. Geredeli
ABS TRACT Objective: Our study aimed to analyze imatinib’s efficacy, tolerability, and safety in treating naive patients with unresectable and progressive desmoid tumors. Material and Methods: The data of patients who were ≥ 18 years old diagnosed with desmoid tumors treated with imatinib were evaluated retrospectively regarding their demographic features, comorbidities, disease stage, pathological features of the tumor, response rates and progression-free survival (PFS). Results: In our study, 36 patients with advanced desmoid tumors receiving imatinib with a median age of 28 [interquartile range (IQR): 21-40] years-old of whom 58.3% were female were included. The patient’s complete response, partial response, stable disease, and progressive disease with imatinib 800 mg/day were 13.9%, 44.4%, 27.7%, and 13.9%, respec-tively. The Grade-3 adverse events, including neutropenia (n=3, 8.3%) and rash (n=3, 8.3%), were relieved after dose reduction. The median PFS was 29 months (95% confidence interval, 16-42 months) with imatinib, and only 3 (8.3%) patients were exitus due to disease progression during the follow-up (median: 43 months, IQR: 24.3-70.8). Conclusion: Our study provided clinical evidence of the efficacy and safety of imatinib in patients with desmoid tumors with real-world experience. However, appropriately designed randomized-controlled clinical trials are needed to explore the effectiveness of imatinib in desmoid tumors to provide an alternative management approach.
{"title":"Efficacy of Imatinib on Advanced and Refractory Desmoid Tumors: A Retrospective Study","authors":"M. Atçı, O. Can, Şaban Seçmeler, A. Sakin, S. Ay, Ş. Cihan, O. Selvi, Ç. Geredeli","doi":"10.37047/jos.2021-87391","DOIUrl":"https://doi.org/10.37047/jos.2021-87391","url":null,"abstract":"ABS TRACT Objective: Our study aimed to analyze imatinib’s efficacy, tolerability, and safety in treating naive patients with unresectable and progressive desmoid tumors. Material and Methods: The data of patients who were ≥ 18 years old diagnosed with desmoid tumors treated with imatinib were evaluated retrospectively regarding their demographic features, comorbidities, disease stage, pathological features of the tumor, response rates and progression-free survival (PFS). Results: In our study, 36 patients with advanced desmoid tumors receiving imatinib with a median age of 28 [interquartile range (IQR): 21-40] years-old of whom 58.3% were female were included. The patient’s complete response, partial response, stable disease, and progressive disease with imatinib 800 mg/day were 13.9%, 44.4%, 27.7%, and 13.9%, respec-tively. The Grade-3 adverse events, including neutropenia (n=3, 8.3%) and rash (n=3, 8.3%), were relieved after dose reduction. The median PFS was 29 months (95% confidence interval, 16-42 months) with imatinib, and only 3 (8.3%) patients were exitus due to disease progression during the follow-up (median: 43 months, IQR: 24.3-70.8). Conclusion: Our study provided clinical evidence of the efficacy and safety of imatinib in patients with desmoid tumors with real-world experience. However, appropriately designed randomized-controlled clinical trials are needed to explore the effectiveness of imatinib in desmoid tumors to provide an alternative management approach.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69821900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Hızal, M. Şendur, B. Bilgin, Ebru KARCI GÜNER, M. Akinci, Y. Ergün, E. Esin, E. B. Köksoy, A. Sezer, N. Özdemir, B. Öksüzoğlu, B. Yalcin, G. Utkan, Y. Ürün
ABS TRACT Objective: Pancreatic cancer is one of the leading causes of cancer-related death. Despite the introduction of new therapeutic agents, survival rates remain low. Furthermore, few trials have evaluated the options for second-line therapy and the prognostic variables. In this study, we aimed to determine the real-world efficacy and prognostic parameters of second-line treatment for advanced pancreatic cancer. Material and Methods: Patients with advanced pancreatic cancer from different centers who received second-line treatment were enrolled in the study. The patients’ demographic, clinical, and pathological characteristics were retrieved retrospectively. Results: A total of 161 pa- tients were enrolled in the study. The majority of the patients (50.3%) received oxaliplatin plus fluoropyrimidine as second-line treatment. The median progression-free survival and overall survival for the entire cohort were 2.5 months and 4.5 months, respectively. In univariate anal- yses, an Eastern Cooperative Oncology Group performance status ≥ 2, age ≥ 65 years, hypoalbuminemia, thrombocytosis, presence of metastatic peritoneal disease, elevated alkaline phosphatase and carcinoembryonic antigen levels, and a neutrophil-lymphocyte ratio (NLR) ≥ 3 were identified as poor prognostic factors. In multivariable analyses, low albumin level (p=0.031) and high NLR (p=0.05) were found to be independent prognostic factors for overall survival. Conclusion: Pancreatic cancer is a unique malignancy, and advanced disease has a dismal prog- nosis. In univariate analyses, we identified multiple factors that were poor prognostic variables. In particular, the albumin level and NLR were independent prognostic factors for overall survival, and these parameters might be useful in selecting the second-line treatment and pre- dicting the survival of these patients.
{"title":"The Real-Life Efficacy of the Second Line Treatment Strategy in Advanced Pancreas Cancer","authors":"M. Hızal, M. Şendur, B. Bilgin, Ebru KARCI GÜNER, M. Akinci, Y. Ergün, E. Esin, E. B. Köksoy, A. Sezer, N. Özdemir, B. Öksüzoğlu, B. Yalcin, G. Utkan, Y. Ürün","doi":"10.37047/jos.2022-88853","DOIUrl":"https://doi.org/10.37047/jos.2022-88853","url":null,"abstract":"ABS TRACT Objective: Pancreatic cancer is one of the leading causes of cancer-related death. Despite the introduction of new therapeutic agents, survival rates remain low. Furthermore, few trials have evaluated the options for second-line therapy and the prognostic variables. In this study, we aimed to determine the real-world efficacy and prognostic parameters of second-line treatment for advanced pancreatic cancer. Material and Methods: Patients with advanced pancreatic cancer from different centers who received second-line treatment were enrolled in the study. The patients’ demographic, clinical, and pathological characteristics were retrieved retrospectively. Results: A total of 161 pa- tients were enrolled in the study. The majority of the patients (50.3%) received oxaliplatin plus fluoropyrimidine as second-line treatment. The median progression-free survival and overall survival for the entire cohort were 2.5 months and 4.5 months, respectively. In univariate anal- yses, an Eastern Cooperative Oncology Group performance status ≥ 2, age ≥ 65 years, hypoalbuminemia, thrombocytosis, presence of metastatic peritoneal disease, elevated alkaline phosphatase and carcinoembryonic antigen levels, and a neutrophil-lymphocyte ratio (NLR) ≥ 3 were identified as poor prognostic factors. In multivariable analyses, low albumin level (p=0.031) and high NLR (p=0.05) were found to be independent prognostic factors for overall survival. Conclusion: Pancreatic cancer is a unique malignancy, and advanced disease has a dismal prog- nosis. In univariate analyses, we identified multiple factors that were poor prognostic variables. In particular, the albumin level and NLR were independent prognostic factors for overall survival, and these parameters might be useful in selecting the second-line treatment and pre- dicting the survival of these patients.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69822206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ABS TRACT Objective: Patient prognosis is determined not only based on tumor characteristics, host inflammation and the immune-nutri- tional index are also important. The aim of the study was to investigate the prognostic and predictive role of pretreatment immune-inflam-mation-nutritional biomarkers in patients with advanced non-small cell lung cancer who were treated with immune checkpoint inhibitors (ICIs). Material and Methods: All consecutive patients aged over 18 years who were treated with at least one cycle of ICIs at our centers were retrospectively reviewed. We evaluated modified Glasgow Prognostic Score (mGPS), Lung Immune Prognostic Index, serum C-reac- tive protein (CRP) and lactate dehydrogenase (LDH) as candidate predictors for response and survival. Results: A total of 102 patients who were treated with ICIs between March 2017 and October 2021 were reviewed. Among the patient cohort, 46.1% and 53.9% were treatment- naive and platinum pretreated, respectively. Programmed death ligand-1 positivity (p=0.048), presence of bone metastasis (p=0.048), increasing serum CRP levels (p=0.018), and mGPS 1 (p=0.040) were independently associated with inferior progression-free survival. Presence of liver metastasis (p=0.036), serum LDH level>upper level of normal (p=0.048), Eastern Cooperative Oncology Group Performance Status (ECOG PS) 2 (p=0.026), and increasing CRP levels (p<0.001) were independently associated with poorer overall survival. ECOG PS 2 (p=0.001), the presence of bone metastasis (p=0.049), and mGPS 1 (p=0.016) were independently associated with poorer disease control rate. Conclusion: We found that immune-inflammation-nutritional parameters were reliable prognostic and predictive biomarkers to select pa- tients with a greater likelihood of benefiting
{"title":"Association of the Immune-Inflammation-Nutritional Parameters with Immune Checkpoint Inhibitor Outcomes in Patients with Advanced Non-Small Cell Lung Cancer","authors":"Ömer Diker, P. Olgun","doi":"10.37047/jos.2021-87477","DOIUrl":"https://doi.org/10.37047/jos.2021-87477","url":null,"abstract":"ABS TRACT Objective: Patient prognosis is determined not only based on tumor characteristics, host inflammation and the immune-nutri- tional index are also important. The aim of the study was to investigate the prognostic and predictive role of pretreatment immune-inflam-mation-nutritional biomarkers in patients with advanced non-small cell lung cancer who were treated with immune checkpoint inhibitors (ICIs). Material and Methods: All consecutive patients aged over 18 years who were treated with at least one cycle of ICIs at our centers were retrospectively reviewed. We evaluated modified Glasgow Prognostic Score (mGPS), Lung Immune Prognostic Index, serum C-reac- tive protein (CRP) and lactate dehydrogenase (LDH) as candidate predictors for response and survival. Results: A total of 102 patients who were treated with ICIs between March 2017 and October 2021 were reviewed. Among the patient cohort, 46.1% and 53.9% were treatment- naive and platinum pretreated, respectively. Programmed death ligand-1 positivity (p=0.048), presence of bone metastasis (p=0.048), increasing serum CRP levels (p=0.018), and mGPS 1 (p=0.040) were independently associated with inferior progression-free survival. Presence of liver metastasis (p=0.036), serum LDH level>upper level of normal (p=0.048), Eastern Cooperative Oncology Group Performance Status (ECOG PS) 2 (p=0.026), and increasing CRP levels (p<0.001) were independently associated with poorer overall survival. ECOG PS 2 (p=0.001), the presence of bone metastasis (p=0.049), and mGPS 1 (p=0.016) were independently associated with poorer disease control rate. Conclusion: We found that immune-inflammation-nutritional parameters were reliable prognostic and predictive biomarkers to select pa- tients with a greater likelihood of benefiting","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69822354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：